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Abstract
Introduction: Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with a gender bias towards major
prevalence in male individuals. Several data suggest the involvement of oxidative stress and mitochondrial
dysfunction in its pathogenesis, though differences between genders have not been evaluated. For this reason, we
analysed features of mitochondrial oxidative metabolism, as well as mitochondrial chain complex enzyme activities
and protein expression, lipid profile, and protein oxidative stress markers, in the Cu,Zn superoxide dismutase with
the G93A mutation (hSOD1-G93A)- transgenic mice and Neuro2A(N2A) cells overexpressing hSOD1-G93A.
Results and Conclusions: Our results show that overexpression of hSOD1-G93A in transgenic mice decreased
efficiency of mitochondrial oxidative phosphorylation, located at complex I, revealing a temporal delay in females
with respect to males associated with a parallel increase in selected markers of protein oxidative damage. Further,
females exhibit a fatty acid profile with higher levels of docosahexaenoic acid at 30 days. Mechanistic studies
showed that hSOD1-G93A overexpression in N2A cells reduced complex I function, a defect prevented by 17β-
estradiol pretreatment. In conclusion, ALS-associated SOD1 mutation leads to delayed mitochondrial dysfunction in
female mice in comparison with males, in part attributable to the higher oestrogen levels of the former. This study
is important in the effort to further understanding of whether different degrees of spinal cord mitochondrial
dysfunction could be disease modifiers in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS, OMIM #105400),
the motor neuron disorder with the highest level of oc-
currence in adult humans, is characterized by a progres-
sive loss of upper and lower motor neurons that leads to
muscular atrophy, paralysis, and death after an average
disease duration of 3 years [1]. The most common form
of ALS is sporadic, having no apparent inheritability,
whereas the dominantly inherited familial ALS accounts
for only about 5–10 % of all ALS patients [2, 3]. Among
the genetic causes of ALS, 15–20 % of familial ALS cases
and about 5 % of sporadic ALS cases are associated with
multiple mutations in the gene for Cu,Zn-superoxide
dismutase (SOD1), which imparts an increase in a novel
toxic function to this otherwise superoxide radical scav-
enging enzyme in normal conditions [4]. Mutated SOD1
forms misfold, aggregate, and accumulate primarily in
spinal cord motor neurons and glial cells of ALS patients
[5]. Furthermore, transgenic mice overexpressing mutant
forms of the human sod1 gene develop a progressive
motor neuron syndrome similar to the human ALS
phenotype [6, 7] and they have been extensively used as
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an experimental model to gain insight into the patho-
genesis of ALS. In particular, one of the most studied
mutations is the substitution of glycine for alanine in the
93th residue (hSOD1-G93A).
Nonetheless, individual factors could help to explain
the great clinical heterogeneity of this disease, with simi-
lar mutations leading to markedly clinically different dis-
ease forms. Among these factors, gender differences in
many neurodegenerative diseases are observed across
epidemiologic studies, pathophysiology, and treatments
[8, 9]. ALS is no exception; its incidence (male: female
ratio 3:1) and prevalence are higher in men than in
women, with a predominance of men with younger dis-
ease onset. Clinical phenotypes are also different in male
and female patients, especially regarding the site of onset
of weakness, as well as cognitive impairment [10, 11].
The aforementioned gender differences have been re-
ported both in studies that included all ALS patients
(sporadic and familial) and in familial ALS cases studied
separately [12]. Lending further support to the greater
occurrence of familial ALS in men than in women, data
extracted from the ALSoD website (http://alsod.iop.kcl.a-
c.uk) revealed a 1.5 male/female ratio for most mendelian
ALS-related mutant genes, including SOD1. Moreover, it
has been reported that gender can account for variations
in the course of disease in familial ALS [13].
Most neurodegenerative disorders involve either caus-
ally or consequently mitochondrial abnormalities [14–17].
Although the underlying causes of motor neuron de-
generation in ALS remain largely unknown, ALS-causing
SOD1 mutations lead to mitochondrial dysfunction,
among multiple pathogenic pathways also present in spor-
adic ALS, such as oxidative stress and endoplasmic
reticulum stress [18–21]. Mitochondrial dysfunction
may also directly provoke cell death by activating the
apoptotic cascade, due to misfolded or aggregated
SOD1 that results either in aberrant localization and re-
lease of proapoptotic factors or binding to apoptotic in-
hibitors [22].
Studies in different species have reported that mito-
chondria in females are more differentiated, and as a re-
sult, the mitochondria show greater capacity for and
efficiency in substrate oxidation than in males. These
features of female mitochondria have been described in
nervous tissue, among other organs and tissues [23–27].
On the other hand, results of several authors suggest a
greater sensitivity of males to mitochondrial dysfunction
compared to females, including higher permeability of
the outer and inner mitochondrial membranes with in-
creased translocation of apoptosis-inducing factor to the
nucleus in neurons from immature rat brains submitted
to hypoxia-ischemia [28]. In brain, among other mito-
chondrial properties more pronounced in males than fe-
males are lower mitochondrial electron transport chain
complex activities, diminished mitochondrial mass, and
lower mitochondrial membrane potential [29, 30].
Taking this background into account, the aim of this
work was to study whether gender-related differences in
spinal cord mitochondrial function of a mouse model of
ALS could contribute to less severe female phenotypes. We
hypothesized that differences in the degree of spinal cord
mitochondria dysfunction between male and female
hSOD1-G93A mice could explain, at least in part, their dif-
ferent clinical features. These data will be helpful to further
understanding of whether different degrees of spinal cord
mitochondrial dysfunction are related to the earlier onset
and faster disease progression in male ALS patients than in
their female counterparts. Moreover, understanding the
causes of the sex differences in ALS could yield clues con-
cerning the pathophysiology of this devastating disease.
Materials and methods
Chemicals
All reagents, unless stated otherwise, were purchased from
Sigmα–Aldrich (St. Louis, MO). Cell culture media, sera,
antibiotics, media supplements, and Lipofectamine 2000®
were obtained from Invitrogen. 17β-estradiol (E2) was dis-
solved in ethanol at a concentration of 1 mM, further di-
luted to 40 μM with culture medium, aliquoted, and
stored frozen for up to one month at -20 °C. E2 stock so-
lutions were used for a final concentration of 10 nM.
Animals and phenotype analyses
A colony of the strain B6SJL-Tg (SOD1-G93A)1Gur/J
(JAX catalogue stock number 002726; from now on
G93A mice) was purchased from The Jackson Labora-
tories (Bar Harbor, ME), maintained in the B6SJL back-
ground, and genotyped as indicated in Additional file 1.
Non-transgenic littermates (from now on Control mice)
were used as controls. Animals were maintained under a
constant 12 h light–dark cycle in individual cages after
weaning (day 21) with temperatures around 22 ± 4 °C,
and fed standard rodent chow and water ad libitum.
For the phenotype analyses, animals were weighed
weekly, and daily for those under stride length analysis.
A third-order polynomial curve was fitted to the age-
body weight sets of data with Prism 6.0 software (Graph-
Pad, La Jolla, CA) in order to calculate maximum weight
and age of attaining maximum weight, and to interpolate
age attaining maximum weight minus 10 %. Neuro-
logical scoring, paw print analysis, and end-point deter-
mination were performed on alternate days starting from
day 60; these are further described in the Additional file 1.
All experimental procedures were approved by the Ethical
Committee for Animal Testing of the Institut de Recerca
Biomèdica de Lleida (IRBLleida) and conformed to Direct-
ive 2010/63/EU of the European Parliament.
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Spinal cord sample preparation
Animals were sacrificed by cervical dislocation at indi-
cated times after being fasted overnight. Spinal cord
lumbar sections were rapidly excised and kept in ice-
cold saline to perform respirometry, or frozen in liquid
nitrogen and stored at -80 °C for further analysis,
respectively. For fatty acid, oxidative markers and
western-blot frozen samples were thawed on ice and ho-
mogenized at 0 °C in a buffer containing 180 mM KCl,
5 mM 3-[N-morpholino]propanesulfonic (MOPS) acid,
2 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
diethylenetriaminepentaacetic acid, 1 μM freshly
prepared butylated hydroxyl toluene (BHT), 10 μg/ml
aprotinin, and 1 mM phenylmethylsulfonyl fluoride
(PMSF), at pH 7.3 using a Potter-Elvehjem motor-
driven glass-Teflon homogenizer. After a brief centrifu-
gation (500 x g, 5 min) to pellet cellular debris, protein
concentrations were measured in the supernatants using
the Bradford assay.
A small set of animals (n = 5 per gender, age 90 days)
was employed for immunohistochemistry. Briefly, after
rapid extraction of spinal cords, these were fixed using
paraformaldehyde and cryoprotected using a sucrose
30 % solution in phosphate buffer. After that, spinal
cords sections (16 μm) were obtained using a Leica
CM3000 cryostat (Leica Microsystems GmbH, Wetzlar,
Germany) and immunohistochemistry was performed
using anti-p21 (1:500, ref. ab7960, Abcam Co, Cambridge,
UK) and SMI-32 (1:500, Stenberger monoclonals; Bio-
legend, San Diego, CA).
Cell culture and transfection
Neuro-2A cell line was obtained from ATCC (#CCL-131)
and grown in Advanced-Minimum Essential Medium
(MEM) without phenol red supplemented with 10 % heat
inactivated fetal bovine serum, 2 mM L-glutamine, 20 U/ml
penicillin, and 20 μg/ml streptomycin. Cells were kept at
37 °C in a humidified atmosphere with 5 % CO2.
After 10 days of pre-treatment with 10nM E2 or vehicle,
cells were harvested, counted, and subcultured in 6-well
plates (200,000 cells per well). The day after plating, rans-
fection was performed using Lipofectamine 2000 (Invitro-
gen, El Prat de Llobregat, Barcelona, Spain) according to
the manufacturer’s instructions. Briefly, lipofectamine and
selected DNA plasmids were mixed (1 μg of DNA/1 μL of
lipofectamine) with Optimen medium (Invitrogen) for
20 min and the resulting mixture was dispensed to the cell
cultures (10 μg DNA per well). The plasmids pEGFP-G93-
hSOD1 and pEGFP-wt-hSOD1, expressing G93A mutant
or non-mutated human SOD1 tagged with enhanced
green fluorescent protein (EGFP), respectively, were kindly
provided by Dr Josep Esquerda (Lleida, Spain). The pEGFP
expression vector was used for mock transfection.
High resolution respirometry
Fresh spinal cords were rinsed with ice-cold normal sa-
line and cut into slices with a tissue chopper adjusted to
a cut width of 300 μm. O2 consumption of sets of 5 lum-
bar spinal cord slices (LSCS) or suspensions of N2A cells
(100,000 cells/mL) was measured at 37 °C with high-
resolution respirometry, both in routine setup (without
additional substrates or effectors) and in permeabilized
conditions (including substrates and inhibitors of spe-
cific respiratory complexes) using an Oxygraph-2 k
(Oroboros Instruments, Innsbruck, Austria) with chamber
volumes set at 2 mL as detailed in the Additional file 1.
Western blot analysis
The content of specific mitochondrial respiratory chain
complexes was estimated in Neuro-2A cells using West-
ern blot analysis. Equal amounts of protein (10–25 μg)
were separated by SDS-PAGE gels. Proteins were trans-
ferred using a Mini Trans-Blot Transfer Cell (BioRad) to
polyvinylidene difluoride membranes (Immobilon-P,
Millipore). Immunodetection was performed using specific
antibodies for the 39 kDa (NDUFA9; CI) subunit of com-
plex I (1:1000), 70 kDa subunit (Flavoprotein) of complex II
(1:500), 29 kDa (Rieske iron-sulfur protein; CIII) subunit of
complex III (1:1000), and COXI subunit of complex IV
(1:1000) (ref. A21344, A11142, A21346, and A6403, re-
spectively; Molecular Probes, Eugene, OR).
Expression of mutant and wild type human SOD1 in
transfected N2A cells was immunodetected using a
monoclonal antibody specific against human SOD1
(Abcam AB52950). Antibodies to porin (1:5000, A31855,
Molecular Probes) and β-actin (1:5000, AB20272, Abcam,
Cambridge, MA), as a control for total mitochondrial
mass or total protein charge, were also used in order to
determine the proportion of protein levels to total mito-
chondrial mass or total protein content. Appropriate
peroxidase-coupled secondary anti-rabbit antibodies
(1:40000, Pierce, Rockford, IL, USA) or anti-mouse anti-
bodies (1:10000, GE Healthcare, UK) and chemilumi-
nescence horseradish peroxidase substrate (Millipore,
Billerica, MA) were used for primary antibody detection.
Signal quantification and recording was performed with a
Chemi-Doc unit (Bio-Rad Laboratories, Inc.). Protein con-
centration was determined with the Bradford method.
Data were expressed as arbitrary units.
Oxidation-derived protein damage marker measurements
by gas chromatography coupled to mass spectrometry
(GC/MS) and fatty acid analyses
Glutamic semialdehyde (GSA), aminoadipic semialdehyde
(AASA), Nε- (carboxyethyl)-lysine (CEL), Nε-(carboxy-
methyl)-lysine (CML), and Nε-(malondialdehyde)-lysine
(MDAL) concentrations in total proteins from spinal cord
homogenates were measured with GC/MS as previously
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described [31] using deuterated internal standards for
each protein oxidative modification adduct as further de-
scribed in the Additional file 1.
Fatty acid analysis in tissue samples was performed as
previously described [31] by gas chromatography after
fatty acid transesterification. Further details are present
in the Additional file 1.
Cytotoxicity assay and ATP content
Viability of N2A cells was assessed with a lactate de-
hydrogenase (LDH)Cytotoxicity Assay Kit (Promega,
Madison, WI) according to manufacturer’s instructions.
Briefly, the amount of LDH released into the culture
medium is measured using an enzymatic reaction that
results in a red formazan product that can be measured
spectrophotometrically. Cell viability was evaluated
relative to the total LDH from whole cell lysate and the
results were expressed as the percentage of viability
versus treated with vehicle and/or mock transfected
cells.
ATP content in N2A cell homogenates was measured
with the ATP Bioluminiscent Assay Kit (Sigma) accord-
ing to the manufacturer’s instructions. Results are
expressed as nanomole ATP per milligram protein.
Statistical analysis
All statistical analyses were performed using the SPSS
software (SPSS Inc., Chicago, IL) or the Prism software
(GraphPad Software). Differences between groups were
analyzed with the Student’s t tests or ANOVA with
Post-Hoc analyses, after normality of variable distribu-
tion was ensured by Kolmogorov-Smirnov test. Correla-
tions between variables were evaluated with the
Pearson’s statistic. For multivariate analysis of fatty acid
composition, the Metaboanalyst platform was used after
autoscaling and log transformation of the relative abun-
dances of their composition [32]. The 0.05 level was se-
lected as the point of minimal statistical significance in
every comparison.
Results and discussion
Disease onset, clinical evolution and survival in G93A
mice show gender dimorphism with a less severe
phenotype in female mice
Our G93A mouse colony exhibited a phenotype consist-
ent with the overexpression of the hSOD1-G93A trans-
gene [33]. G93A mice gained weight and reached a
higher maximum value for males than for females (21.1 ±
0.2 g vs 18.0 ± 0.1 g, respectively p < 0.05) though mice
from both genders decreased to a similar body mass when
approaching endpoint (Fig. 1a). In comparison, control
mice exhibit continuously gender dimorphism in weight
(Additional file 2: Figure S1). Onset of clinical symptoms
occurred by approximately 70–90 days of age followed by
body weight loss, abnormal gait, muscle weakness with
decreased grip strength, and impaired coordination. As an
estimation of disease onset, we used the interpolated
value for age of attaining maximum weight (obtained
after fitting a third-order polynomial to the weight
evolution curve). Maximum body mass was attained at
a significantly younger age in males than in females
(87.9 ± 1.2 vs 95.9 ± 1.0 days; p < 0.05; Fig. 1a and b).
Female G93A mice showed a significant delay in dis-
ease progression, as evidenced by slower rate of weight
loss (Fig. 1b). As a second estimation of disease pro-
gression, stride length was measured with paw print
analysis and in this case the onset of clinical weakness
was quantified by determining the age at which short-
ening of the stride length was lower than 40 % for two
consecutive measures. These measurements again indi-
cate a slower disease progression in female G93A mice,
as this shortening (both for the right and left stride
lengths) in G93A females was attained at a significantly
older age than in their male counterparts (Fig. 1c). An-
imals were euthanized when they demonstrated hind
limb paralysis or inability to right themselves when
placed on their side. Disease duration, estimated as the
time between disease onset (10 % loss of their maximum
weight) and sacrifice, was significantly longer in females
than in males (Fig. 1d). Female G93A mice survived sig-
nificantly longer than males with survival times of 134.1 ±
2.9 days and 124.9 ± 1.5 days (p < 0.01) respectively
(Fig. 1e).
Gender appears to modify the course of disease and
lifespan in other animal models of ALS with mutations
in the hSOD1 gene, with an earlier disease onset in male
transgenic rats and mice overexpressing hSOD1-G93A
[34, 35], although gender appears to have no consistent
effect on survival of ALS patients [36]. To ascertain
whether this was due to different expression of hSOD1-
G93A protein expression, this parameter was evaluated
in spinal cord with western blot analysis, using a mono-
clonal antibody specific against human SOD1, which
has been shown to recognize distinct mutated human
SOD1 forms, including hSOD1-G93A [37]. Additional
file 2: Figure S2 shows the western blot analysis of trans-
genic male and female mice at 30 and 60 days, leading
to the expression of a protein with an apparent MW of
16 kDa, whereas, as expected, the protein was not de-
tected in control mice. These results provide evidence
that while transgenic protein levels, at 30 days, were
higher in males, at 60 days this difference was reversed.
Thus, at 30 days we cannot rule out different levels of
aggregated or aberrant SOD1 activity between male and
female transgenic mice as the primary origin of gender
differences in survival. However, maximum protein
levels of hSOD1-G93A coincide temporally with the late
pre-symptomatic stage and the disease onset.
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Oxygen consumption of mouse lumbar spinal cord slices
shows early mitochondrial impairment in males linked to
complex I dysfunction
Respirometric analysis of mitochondrial function provides
a tool to study changes in mitochondrial respiratory chain
function and mitochondrial ATP production in tissue bi-
opsies, cultured cells, and isolated mitochondria [38]. In
order to assess whether gender-related differences in
spinal cord mitochondrial function could explain longer
survival of female animals, we performed high resolution
respirometry in lumbar spinal cord slices from male and
female mice, both G93A and non-transgenic mice, at sev-
eral ages. First, using intact (not permeabilized) slices,
which resemble in vivo conditions, we found that in G93A
mice routine respiration was 41.7 % higher in females at
end stage (p < 0.05, Fig. 2a), which suggests that mito-
chondrial function is better spared from disease in female
mice, in line with clinical variables.
When comparing the effect of transgene hSOD1-
G93A, overexpression only decreased routine O2 con-
sumption at the later stages of the disease (control vs.
G93A: for males, 37.0 ± 3.8 vs. 22.5 ± 2.7 pmol O2/min/
mg protein, P < 0.01; for females, 40.1 ± 1.5 vs. 31.9 ± 2.8
pmol O2/min/mg protein, p < 0.01; Additional file 2:
Figure S2A and S2B). This may be attributed to the ter-
minal status of the animals and general atrophy of spinal
cords at this stage, while no gender differences appeared
in control mice (Additional file 2: Figure S3A).
However, considering that this difference was only
present at later stages of the disease, we wanted to ex-
plore whether any specific respiratory complex was im-
paired earlier or showed gender related differences. For
this reason we studied the sensitivity to complex inhibi-
tors, a validated technique for molecular disection of
mitochondrial function, as described in the Materials
and methods section. Complex I respiration in G93A fe-
males was greater than in males at 60 (20.3 %, p =
0.076), 90 (31.4 %, p < 0.05), and 120 days (25.6 %, p <
0.05) (Fig. 2b). Reinforcing feminine mitochondrial resili-
ence to hSOD1-G93A-linked complex I decay, control-
transgenic comparison offered significant differences
in complex I function in male mice at all ages studied,
whereas transgene only affected complex I activity signifi-
cantly at later stages of the disease in females (Additional
file 2: Figure S2C and S2D). Interestingly, gender-related
differences were found in control animals at the earliest
ages analyzed. Complex I respiration was 39.6 % higher
(p < 0.01) in 30-day-old males, whereas in older animals
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Fig. 1 Gender influences weight changes associated to disease onset and progression (a, b), stride length (c), clinical progression (d), and survival
(e) in hSOD-G93A mice. Weight evolution across age in hSOD-G93A mice a with arrows indicating calculated maximum weight. Bars in b are means ±
SEM of the age at maximum weight or time spent for a 10 % loss from maximum weight, expressed in days. Bars in c are means ± SEM of the age of
clinical onset measured by stride length analysis, expressed in days. Dots in d shows disease duration among the G93A colony, separated by gender,
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way ANOVA. * indicates p < 0.05 between male and female mice of the same age with Student’s t test. **, p < 0.01 after a Kaplan-Meyer analysis
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the values were similar in both genders, lacking signifi-
cant differences (Additional file 2: Figure S3B).
Regarding complex II, no gender differences were
found for G93A animals (Fig. 2c) along disease
progression. Residual oxygen consumption is due to
oxidative side reactions remaining after application of
mitochondrial chain complex III inhibitors, such as
antimycin A. This has been related to reactive oxygen
a b
c d
e f
h i
g
Fig. 2 (See legend on next page.)
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species (ROS) production. Interestingly, no gender-
related differences were found in G93A mice (Fig. 2d).
Antimycin A-resistant respiration was higher in control
than in G93A of both genders both at 30 days and at
120 days (Additional file 2: Figure S2E and S2F). Inter-
estingly, the opposite results were obtained in residual
respiration at 60 days and 90 days, displaying higher
rates in male G93A mice at 60 days (Additional file 2: Fig-
ure S2E) and in female G93A mice at 90 days (Additional
file 2: Figure S2F).
After cell permeabilization for direct evaluation of
mitochondrial function no difference was found for en-
dogenous respiration between genders in G93A, sup-
porting the notion that concentration of metabolites of
mitochondria do not differ between genders (Fig. 2e).
However, complex I-related measures showed higher
capacities for females at early stages: state 2 respiration
for complex I was higher in females than in males in
G93A mice, at a presymptomatic stage (30 days, Fig. 2f ).
Interestingly, O2 consumption of complex I state 3 was
significantly higher in females compared with males all
along disease progression (Fig. 2g). Similarly complexI/II
state 3 measurements show increased consumption in
G93A females in comparison with males (Fig. 2h).
Our results are consistent with previous reports [39]
showing that routine (intact tissue, without any inhibi-
tor) respiration only shows evident reduction in G93A
animals at the end stage of the disease. Although the
routine respiration of intact LSCS was not significantly
different in males and female G93A mice (only at end-
point), the higher rotenone resistant respiration in males
at 60 days suggests a lower complex I contribution to
overall respiration, as calculated by the difference with
respect to routine respiration.
Focusing on the G93A animals, females showed
greater complex I oxygen consumption than males from
60 days. Nevertheless, this advantage was only significant
for 90-day and endpoint animals. Since rotenone-
mediated cytotoxicity was proved to be alleviated in
female neuron primary cultures [40], this decreased res-
piration could contribute to the survival demise in
males. Studies from [41] showed that, in this mouse
model, motor neuron abnormalities begin at 44–60 days.
However, cytosol vacuolization and swollen and mega-
mitochondria were evident before (30 days, even P7). In
line with this we also show early complex I dysfunction
in males. This gender dimorphism can be partially ex-
plained by previous data [42] showing a protective
mechanism of the peroxisome proliferator-activated re-
ceptor gamma coactivator 1-alpha (PGC-1α), a master
metabolic regulator in mammals. As PGC-1α could en-
hance the transcriptional activities of sex hormone
receptors—e.g., androgen receptor [43] or estrogen re-
ceptors [44]—this may result in a feed-back loop, enhan-
cing (in the case of estrogens) survival.
Oxidative stress markers and fatty acid composition of
spinal cord also show gender dimorphism
Since complex I dysfunction is linked to ROS production
and this is related to fatty acid composition of tissues
[45, 46], we measured both structurally defined oxida-
tion products with isotope-dilution GC/MS and fatty
acid profiles of spinal cord. In general, both age and gen-
der influenced, in some cases with significative interac-
tions, the concentrations of oxidative modifications in
proteins from spinal cord lysates (Fig. 3). Regarding as-
sociation with longer survival of females, only AASA
and CEL showed diminished values in spinal cord at
preclinical stages (60 days; Fig. 3b and c), whereas GSA
and CML showed increased concentrations in females at
these stages (Fig. 3a and d), with MDAL showing no
major gender differences. These results contrast with
those obtained examining samples of the human disease.
In previous analyses, significant increases were reported
for ALS samples both in spinal cord and motor cortex
[18], especially evident for lipid peroxidation derived
markers, such as MDAL. These differences could arise
from the effect of overexpressing an antioxidant enzyme
(SOD), in the G93A case, which might blunt potential
overproduction of ROS linked to ALS. To further con-
firm differences in ROS production, we also examined
expression of p21, a protein regulated by oxidative
stress. The results (Fig. 3f and e) are in line with protein
oxidative damage, suggesting that at an early clinical stage
(90 days) oxidative stress in females is higher than in
males. This contrasts with the recently described role of
p21 as a potential disease accelerator in astrocytes [47] or
an ageing hallmark in neurons [48].
It is known that fatty acid profile strongly influences
membrane peroxidizability. Further, fatty acid compos-
ition is associated with changes in survival [49] and
mitochondrial function [50]. For these reasons we
(See figure on previous page.)
Fig. 2 Gender influences O2 consumption in lumbar spinal cord slices from hSOD-G93A mice. Graphs shows baseline (a), complex I (b), complex
II (c), and residual (d) O2 consumption in slices from male and female G93A mice. Measurements were taken at 37 °C in Hank’s balanced
salt solution containing 10 mM Hepes, pH 7.4, and corrected for instrumental background O2 flux. After permeabilization, similar measures
were performed for endogenous (e), complex I state 2 (f), complex I state 3 (g), complex I/II state 3 (h) and complex II state3 (i) O2 consumption.
Measurements were taken at 37 °C in Mir05 media. Values shown are means ± SEM expressed as pmol O2/min · mg protein for 4-6 independent
measures. *, p < 0.01 with respect to females of the same age with Student’s t test
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analysed fatty acid content in G93A mouse spinal cord
at different ages. The results (Fig. 4a and Additional file
2: Figure S4) show that in multivariate analyses the
major determinant for fatty acid composition of spinal
cord in G93A mice was age, with a clear discriminating
effect (partial-least square discriminant analyses accur-
acy 95 %). This was further reinforced by linear general
model analyses, in most of which age was the factor with
the greatest importance. As an example (Table 1), both
for arachidonic and docosahexaenoic acid contents, age
appeared as the predictor factor with highest import-
ance. Interestingly, and reinforcing the importance of
fatty acid composition in this disease, transgene status
also appeared, as the second relevant factor in the
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(e). Values shown are means ± SEM expressed as μmol of analyte per mol lysine. f Representative immunofluorescence image of lumbar spinal
cord slices from G93A mice showing increased p21 levels in females compared with males, as quantified in g. abc indicate, significant effects (p <
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amount of these lipids. Finally, and concerning the influ-
ence of gender, it strongly influences the levels of struc-
turally and functionally relevant docosahexaenoic acid
(Table 1), and its interaction with age and transgen sta-
tus is relevant in the amount of these fatty acids. Overall,
gender, age and transgen status allowed for a model with
a high robustness (R2 = 0.85).
As indicated, the most remarkable change involves the
highly peroxidizable docosahexaenoic acid (DHA), which
showed a 11.7 % increase in female G93A mouse spinal
cord as early as 30 days, with this difference maintained
througout the preclinical ages (Fig. 4b, Tables 2, 3, 4 and
5, p < 0.01), while it was lost at later stages of the disease.
This early increase, based on the neuroprotective role of
some derivates of this fatty acid, could contribute to
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Fig. 4 Age and gender are major factors determining lipid composition in lumbar spinal cords in G93A mice. Partial-least square discriminant
analyses a show that age is the major factor explaining differences in fatty acid composition between G93A samples. Univariate analyses b show
age- and gender-related changes in the amount of docosahexaenoic and arachidonic fatty acids. abc indicate significant effects (p < 0.01) of age,
gender, and their interaction, respectively, after 2 way ANOVA. * shows significant differences for Bonferroni post-hoc analyses (*p < 0.05, **p < 0.01,
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Table 1 Univariant general lineal model linking specific fatty
acid amount with gender, G93A-Transgen status and age, as
well as its interactions
Variable 22:6 n-3 20:4 n-6
F Sig F Sig
Gender 5.372 .023 0.008 .927
G93A Transgen 57.942 .000 25.863 .000
Age 138.614 .000 60.923 .000
Gender-G93A Transgen 12.003 .001 .171 .680
Gender-Age 4.704 .005 4.919 .004
G93A Transgen-Age 7.336 .000 44.616 .000
G93A Transgen-Age-Gender 7.142 .000 1.991 .123
Table 2 Fatty acid composition (% of abundance) spinal cord
(30 days)
Male Female p value
14:0 2,086 ± 0,005 1,961 ± 0,077 0.2
16:0 23,045 ± 0,182 22,985 ± 0,152 0.8
16:1n-7 1,433 ± 0,043 1,325 ± 0,041 0.2
18:0 17,324 ± 0,026 16,808 ± 0,331 0.2
18:1n-9 35,341 ± 0,041 34,552 ± 0,219 0.03
18:2n-6 1,141 ± 0,063 1,907 ± 0,653 0.3
18:3n-3 0,075 ± 0,001 0,067 ± 0,002 0.1
18:4n-6 0,060 ± 0,001 0,058 ± 0,004 0.7
20:0 0,102 ± 0,003 0,101 ± 0,004 0.8
20:1n-9 1,912 ± 0,058 1,658 ± 0,035 0.1
20:2n-6 0,774 ± 0,033 0,778 ± 0,017 0.9
20:3n-6 0,766 ± 0,048 0,779 ± 0,046 0.9
20:4n-6 5,944 ± 0,040 6,183 ± 0,128 0.1
20:5n-3 0,025 ± 0,001 0,022 ± 0,001 0.2
22:0 0,058 ± 0,003 0,056 ± 0,003 0.8
22:4n-6 2,277 ± 0,069 2,246 ± 0,040 0.8
22:5n-6 0,333 ± 0,013 0,307 ± 0,035 0.5
22:5n-3 0,149 ± 0,013 0,160 ± 0,008 0.6
24:0 0,090 ± 0,001 0,135 ± 0,018 0.1
22:6n-3 6,823 ± 0,090 7,687 ± 0,157 0.01
24:5n-3 0,095 ± 0,007 0,107 ± 0,015 0.5
24:6n-3 0,136 ± 0,006 0,107 ± 0,008 0.1
p value reflects statistical significance between hSODG93A Male and
Female animals
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delayed disease phenotypical traits in females. Gender
dimorphism in DHA content has not been previously
documented in ALS. Observational studies in human
children show that females exhibit great benefit from n-
3 dietary intake, in terms of cognitive function [51]. This
is manifested before sexual maturation, so the role of es-
trogens and gestagens could be minor. Interestingly, it
has been observed that n-3 and progesterone interact in
neuroprotection after traumatic brain injury, but infor-
mation on the interaction of feminine hormones with
DHA synthesis or the effects on nervous tissue is scarce.
In this sense, epidemiological and basic studies show the
potential importace of DHA and other n-3 fatty acids in
ALS development [49, 52–54] but to date this is the first
report regarding the gender-specific differences in this
model.
Concerning the potential mechanisms connecting
enhanced DHA amount and female resilience to ALS
development, it should be recalled that DHA is a
precursor of endogenous modulators of neuroinflam-
mation [55]. One of these modulators, resolvin D1
shows a relevant role as inhibitor of inflammatory
cytokine secretion in the same model we have exam-
ined [56].
Overexpression of HSOD1-G93A in Neuro 2A cells leads
to a loss in complex I function which can be prevented
by estradiol
Higher estrogen level in females could explain the
gender-related differences, since these hormones have
mitochondrial effects [57, 58]. To evaluate whether
these could explain gender differences in mitochon-
drial function in G93A mice, we studied the effects of
estradiol preincubation (10 days) in N2A cells ex-
pressing either wild type hSOD1 or G93A-mutated
hSOD1 (both containing EGFP to control transfec-
tion, which achieved 80–90 % efficiency (Additional
file 2: Figure S5). There was no significant difference
in the cell viability between these treatments (Fig. 5a).
Cellular ATP content showed similar results, without
major effects of G93A mutation or estradiol treatment
(Fig. 5b). Mitochondrial function was evaluated as
above. In line with the lack of differences in ATP
concentrations, O2 consumption, both in standard
Table 3 Fatty acid composition (% of abundance) spinal cord
(60 days)
Male Female p value
14:0 1,571 ± 0,050 1,502 ± 0,050 0.3
16:0 20,183 ± 0,106 19,943 ± 0,117 0.1
16:1n-7 1,3876 ± 0,091 1,257 ± 0,063 0.2
18:0 17,072 ± 0,107 17,458 ± 0,187 0.06
18:1n-9 38,651 ± 0,196 37,692 ± 0,230 0.004
18:2n-6 2,059 ± 0,070 1,980 ± 0,032 0.3
18:3n-3 0,082 ± 0,002 0,085 ± 0,005 0.5
18:4n-6 0,205 ± 0,040 0,251 ± 0,007 0.2
20:0 0,4981 ± 0,040 0,454 ± 0,024 0.2
20:1n-9 1,846 ± 0,043 1,802 ± 0,043 0.4
20:2n-6 0,744 ± 0,036 0,764 ± 0,026 0.6
20:3n-6 0,648 ± 0,012 0,666 ± 0,025 0.4
20:4n-6 5,137 ± 0,072 5,411 ± 0,150 0.06
20:5n-3 0,048 ± 0,007 0,275 ± 0,002 0.05
22:0 0,028 ± 0,004 0,019 ± 0,001 0.1
22:4n-6 2,175 ± 0,051 2,338 ± 0,056 0.02
22:5n-6 0,208 ± 0,014 0,239 ± 0,077 0.6
22:5n-3 0,195 ± 0,014 0,190 ± 0,009 0.7
24:0 0,314 ± 0,028 0,295 ± 0,011 0.5
22:6n-3 6,785 ± 0,139 7,475 ± 0,132 0.001
24:5n-3 0,082 ± 0,005 0,058 ± 0,001 0.01
24:6n-3 0,078 ± 0,006 0,082 ± 0,002 0.5
p value reflects statistical significance between hSODG93A Male and
Female animals
Table 4 Fatty acid composition (% of abundance) spinal cord
(90 days)
Male Female p value
14:0 1,362 ± 0,036 1,395 ± 0,058 0.5
16:0 19,191 ± 0,133 18,902 ± 0,249 0.2
16:1n-7 1,219 ± 0,055 1,317 ± 0,034 0.1
18:0 17,866 ± 0,127 17,735 ± 0,187 0.5
18:1n-9 38,326 ± 0,258 39,209 ± 0,349 0.03
18:2n-6 2,239 ± 0,056 1,903 ± 0,082 0.003
18:3n-3 0,128 ± 0,021 0,111 ± 0,005 0.3
18:4n-6 0,134 ± 0,021 0,102 ± 0,011 0.1
20:0 0,418 ± 0,017 0,478 ± 0,026 0.03
20:1n-9 1,888 ± 0,037 1,782 ± 0,015 0.001
20:2n-6 0,694 ± 0,014 0,605 ± 0,010 0.001
20:3n-6 0,598 ± 0,011 0,533 ± 0,006 0.001
20:4n-6 5,538 ± 0,112 5,466 ± 0,080 0.5
20:5n-3 0,038 ± 0,002 0,051 ± 0,006 0.07
22:0 0,017 ± 0,001 0,038 ± 0,006 0.004
22:4n-6 2,357 ± 0,086 2,353 ± 0,042 0.9
22:5n-6 0,296 ± 0,015 0,385 ± 0,059 0.2
22:5n-3 0,202 ± 0,004 0,259 ± 0,011 0.001
24:0 0,295 ± 0,018 0,409 ± 0,021 0.002
22:6n-3 7,039 ± 0,107 6,808 ± 0,067 0.05
24:5n-3 0,060 ± 0,001 0,084 ± 0,008 0.01
24:6n-3 0,090 ± 0,005 0,124 ± 0,012 0.01
p value reflects statistical significance between hSODG93A Male and
Female animals
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culture medium (without additional substrates, inhibitors,
or uncoupling agents) and in non-phosphorylating condi-
tions (after inhibition of mitochondrial chain complex V
F0-ATP synthase with oligomycin), was not different
among treatments (Fig. 5c). This could be explained by
the Warburg effect [59], in which tumoral cells in usual
culture media (having enough glucose) could favour glyco-
lytic procedures over mitochondrial respiration for ATP
production. To establish whether mitochondrial functional
reserves were impaired, we measured maximum respira-
tory capacity (obtained after uncoupling). In line with in
vivo G93A effect in mitochondrial function, the transfec-
tion of G93A-hSOD significantly reduced (p < 0.05) max-
imal respiratory capacity (Fig. 5c). Interestingly, estradiol
pretreatment abbrogated these differences, suggesting that
estrogens could explain the preserved mitochondrial func-
tion present in female transgenic mice. As this respiration
was inhibited by antimycin A to an equal extent in all the
situations, these results point to a complex I malfunction.
To confirm this, we measured O2 consumption after cell
permeabilization (in the presence of mitochondrial sub-
strates and inhibitors). In line with the above results,
neither endogenous respiration (before addition ofs
ubstrates, data not shown) nor complex I state 2 respir-
ation stimulated by glutamate/malate were significantly
different in the examined conditions (data not shown).
However, after the addition of ADP, in order to achieve
complex I state 3 respiration, O2 uptake in G93A-hSOD
transfected cells was lower than in wild type-hSOD or
mock EGFP transfected cells (Fig. 5d, complex I). This
respiration difference was enhanced after the addition of
succinate (Fig. 5d, complex I + II), but disappeared when
rotenone was injected in the measurement chambers
(Fig. 5d, complex II), reinforcing the role of complex I dys-
function. Importantly, estradiol preincubation prevented
the hSOD1-G93A induced differences. In order to assess
the origin of the reduced complex I function, we estimated
the protein expression of complex I by measuring repre-
sentative subunits (complex I: 39KDa,NDUFA9; complex
II: 70KDa, Flavoprotein; complex III: 29 kDa Rieske iron-
sulfur protein; complex IV: COXI subunit of complex IV).
Figure 5e shows that levels of complex I peptides do not
differ among the treatments, suggesting that either the
dysfunction is induced by loss of other peptides and/or by
dysfunction of complex I without changes in the amount
of their components. Levels of the other peptides exam-
ined were not different (data not shown). Considering that
estrogens do not lead to changes in mitochondrial com-
plex expression, this suggest that there is a greater effi-
ciency in terms of ATP production in females. This could
enhance their homeostatic capacities, therefore supporting
an enhanced response against bioenergetic failure in spinal
cord of G93A mice and, possibly, ALS patients, by chan-
ging the expression of other mitochondrial proteins. In
line with this, researchers have focused on gender rele-
vance in the mitochondrial permeability transition pore
formation in the hSOD1-G93A mouse model [60]. Hence,
they demonstrated that ablation of cyclophilin D (a pro-
tein structurally linked to the mitochondrial permeability
membrane transition pore) completely abolished the
phenotypic advantage of female hSOD-G93A, with no
major effect found in males. In fact, they showed that 17β-
estradiol protected hSOD1-G93A expressing cortical neu-
rons and spinal cord motor neurons against glutamate
toxicity in brain mitochondria, but the protection was lost
in neurons lacking cyclophilin D. All in all, our results
suggest that mitochondrial complex activities could be
relevant disease modifiers in ALS. Confirming this, very
recent data [61] show that even in peripheral blood cells,
ALS is associated with decreased complex I activity.
As limitations of this work we acknowledge that mea-
surements performed in total spinal cord, either fatty
acid composition, oxidative damage or mitochondrial
function, do not allow to specify the cell involved. Thus,
we do not know whether the in vivo effect of gender is
located in neurons, glia or both. Also, important
Table 5 Fatty acid composition (% of abundance) spinal cord
(120 days)
Male Female p value
14:0 1,128 ± 0,243 1,461 ± 0,107 0.1
16:0 19,346 ± 0,314 19,983 ± 0,380 0.07
16:1n-7 1,193 ± 0,178 1,338 ± 0,193 0.1
18:0 17,274 ± 0,243 17,452 ± 0,206 0.3
18:1n-9 40,311 ± 0,559 39,427 ± 0,454 0.1
18:2n-6 2,076 ± 0,071 1,968 ± 0,120 0.5
18:3n-3 0,149 ± 0,005 0,146 ± 0,006 0.7
18:4n-6 0,214 ± 0,010 0,207 ± 0,014 0.4
20:0 0,429 ± 0,020 0,497 ± 0,038 0.1
20:1n-9 1,644 ± 0,018 1,675 ± 0,064 0.8
20:2n-6 0,502 ± 0,022 0,478 ± 0,017 0.1
20:3n-6 0,619 ± 0,029 0,591 ± 0,023 0.2
20:4n-6 6,101 ± 0,112 5,758 ± 0,171 0.06
20:5n-3 0,078 ± 0,016 0,090 ± 0,012 0.6
22:0 0,069 ± 0,005 0,095 ± 0,007 0.03
22:4n-6 2,138 ± 0,068 1,902 ± 0,059 0.008
22:5n-6 0,193 ± 0,017 0,226 ± 0,033 0.3
22:5n-3 0,244 ± 0,007 0,247 ± 0,011 0.9
24:0 0,584 ± 0,023 0,659 ± 0,039 0.1
22:6n-3 5,533 ± 0,055 5,612 ± 0,100 0.7
24:5n-3 0,061 ± 0,008 0,062 ± 0,004 0.9
24:6n-3 0,106 ± 0,012 0,116 ± 0,014 0.6
p value reflects statistical significance between hSODG93A Male and
Female animals
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differences in oxidative metabolism in skeletal muscle
between males and females cannot be neglected [24],
and it may be very relevant in ALS development. Fur-
ther, a recent metaanalysis review indicates that some of
the gender related differences in survival present in this
model may be related to the genetic background
[62]. This indicates that the relationship between
gender, disease development and mitochondrial function
is complex. Furthermore, mitochondrial vacuolisation and
degeneration is a dominant and early phenomenon in
the mouse used in this study, a fact that may be at-
tributed to excessive SOD1 overexpression. However,
the in vitro experiments demonstrating loss of com-
plex I function, without cell death, and the preventive
role of estrogens in this phenomenon, point out that
even subtle endocrine effects on mitochondrial func-
tion could be relevant at long term. The mechanisms
behind the gender and background sparing effects on
the pathogenic burden of overexpression of mutant
SOD1 merit further exploration, but our data show
that this should comprise evaluation of mitochondrial
function and fatty acid composition.
Even accounthing these limitations, we have described
an early mitochondrial defect during the presymptomatic
stage associated with the expression of G93A-mutated hu-
man SOD1 that appears at a younger age in male mice
than in females, correlating with the delay in the clinical
features of ALS-like phenotype.
Conclusions
Our data support a role for dysfunctional mitochondria
in ALS pathogenesis and, in particular, the gender bias
towards males observed in ALS. This is added to
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changes in fatty acid composition and oxidative stress
markers. These factors could be disease modifiers, affect-
ing the phenotypic differences among ALS patients.
Furhter, mitochondrial targets such as complex I may
represent a viable focus for novel treatments of a range
of disorders affecting motor systems. The presented
data, finally, underlines the importance of further studies
directed at establishing the role of sex hormones and re-
lated molecules in an ALS cure.
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